Phase 4Completed
Hepato-renal Regulation of Water Conservation in Heart Failure Patients With SGLT-2 Inhibitor Treatment (DAPA-Shuttle1)
- Sponsor
- National Heart Centre Singapore (Academic or other)
- Enrollment
- 40 enrolled
- Conditions
- Diabetes Mellitus; Heart Failure
- Interventions
- Dapagliflozin 10 MG [Forxiga]
- Ages
- adults, older adults
- Registry
- NCT04080518
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to investigate the effects of Dapagliflozin (FORXIGA) 10mg (n=20) and placebo (n=20) on the renal concentration mechanism, mobilization of Na+ from tissue stores, and mobilization of muscle glycogen and fat, in patients heart failure NYHA classes I and II,with or w/o T2DM in a 4-week double-blind, placebo-controlled, randomized study with 2 treatment arms.
Primary outcomes
- To demonstrate that SGLT-2 inhibition induces urea-dominated renal water conservation within the renal concentration mechanism. ( Change from baseline in urinary osmolyte concentration
History
Last registry update
Primary completion
Started
Registered
Papers citing this trial
- Water Conservation Overrides Osmotic Diuresis During SGLT2 Inhibition in Patients With Heart Failure
Journal of the American College of Cardiology